vs
Apellis Pharmaceuticals, Inc.（APLS）与ESCO TECHNOLOGIES INC（ESE）财务数据对比。点击上方公司名可切换其他公司
ESCO TECHNOLOGIES INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.4倍（$289.7M vs $199.9M），ESCO TECHNOLOGIES INC净利率更高（9.9% vs -29.5%，领先39.4%），ESCO TECHNOLOGIES INC同比增速更快（17.3% vs -5.9%），ESCO TECHNOLOGIES INC自由现金流更多（$63.0M vs $-14.3M），过去两年ESCO TECHNOLOGIES INC的营收复合增速更高（7.8% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
ESCO是来自新加坡的品牌，专注于实验室领域相关产品及服务的研发、生产与销售，可为各类科研、检测及工业实验室提供适配的产品解决方案与配套支持，产品广泛应用于生命科学、医疗健康、工业检测等多个领域。
APLS vs ESE — 直观对比
营收规模更大
ESE
是对方的1.4倍
$199.9M
营收增速更快
ESE
高出23.2%
-5.9%
净利率更高
ESE
高出39.4%
-29.5%
自由现金流更多
ESE
多$77.2M
$-14.3M
两年增速更快
ESE
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $289.7M |
| 净利润 | $-59.0M | $28.7M |
| 毛利率 | — | 41.4% |
| 营业利润率 | -25.6% | 13.2% |
| 净利率 | -29.5% | 9.9% |
| 营收同比 | -5.9% | 17.3% |
| 净利润同比 | -62.2% | 22.2% |
| 每股收益（稀释后） | $-0.40 | $1.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSESE
| Q4 25 | $199.9M | $289.7M | ||
| Q3 25 | $458.6M | $286.5M | ||
| Q2 25 | $178.5M | $296.3M | ||
| Q1 25 | $166.8M | $265.5M | ||
| Q4 24 | $212.5M | $247.0M | ||
| Q3 24 | $196.8M | $298.5M | ||
| Q2 24 | $199.7M | $260.8M | ||
| Q1 24 | $172.3M | $249.1M |
净利润APLSESE
| Q4 25 | $-59.0M | $28.7M | ||
| Q3 25 | $215.7M | $218.7M | ||
| Q2 25 | $-42.2M | $26.1M | ||
| Q1 25 | $-92.2M | $31.0M | ||
| Q4 24 | $-36.4M | $23.5M | ||
| Q3 24 | $-57.4M | $34.3M | ||
| Q2 24 | $-37.7M | $29.2M | ||
| Q1 24 | $-66.4M | $23.2M |
毛利率APLSESE
| Q4 25 | — | 41.4% | ||
| Q3 25 | — | 45.9% | ||
| Q2 25 | — | 41.2% | ||
| Q1 25 | — | 41.1% | ||
| Q4 24 | — | 39.8% | ||
| Q3 24 | — | 40.1% | ||
| Q2 24 | — | 39.6% | ||
| Q1 24 | — | 38.8% |
营业利润率APLSESE
| Q4 25 | -25.6% | 13.2% | ||
| Q3 25 | 48.7% | 17.2% | ||
| Q2 25 | -18.6% | 11.2% | ||
| Q1 25 | -50.0% | 15.3% | ||
| Q4 24 | -12.3% | 11.4% | ||
| Q3 24 | -24.0% | 14.8% | ||
| Q2 24 | -14.7% | 14.3% | ||
| Q1 24 | -36.0% | 11.7% |
净利率APLSESE
| Q4 25 | -29.5% | 9.9% | ||
| Q3 25 | 47.0% | 76.3% | ||
| Q2 25 | -23.6% | 8.8% | ||
| Q1 25 | -55.3% | 11.7% | ||
| Q4 24 | -17.1% | 9.5% | ||
| Q3 24 | -29.2% | 11.5% | ||
| Q2 24 | -18.9% | 11.2% | ||
| Q1 24 | -38.5% | 9.3% |
每股收益（稀释后）APLSESE
| Q4 25 | $-0.40 | $1.11 | ||
| Q3 25 | $1.67 | $8.43 | ||
| Q2 25 | $-0.33 | $1.01 | ||
| Q1 25 | $-0.74 | $1.20 | ||
| Q4 24 | $-0.30 | $0.91 | ||
| Q3 24 | $-0.46 | $1.32 | ||
| Q2 24 | $-0.30 | $1.13 | ||
| Q1 24 | $-0.54 | $0.90 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $103.8M |
| 总债务越低越好 | — | $145.5M |
| 股东权益账面价值 | $370.1M | $1.6B |
| 总资产 | $1.1B | $2.4B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资APLSESE
| Q4 25 | $466.2M | $103.8M | ||
| Q3 25 | $479.2M | $101.3M | ||
| Q2 25 | $370.0M | $78.7M | ||
| Q1 25 | $358.4M | $57.4M | ||
| Q4 24 | $411.3M | $71.3M | ||
| Q3 24 | $396.9M | $66.0M | ||
| Q2 24 | $360.1M | $63.0M | ||
| Q1 24 | $325.9M | $59.4M |
总债务APLSESE
| Q4 25 | — | $145.5M | ||
| Q3 25 | — | $186.0M | ||
| Q2 25 | — | $525.0M | ||
| Q1 25 | — | $88.0M | ||
| Q4 24 | — | $112.0M | ||
| Q3 24 | — | $122.0M | ||
| Q2 24 | — | $173.0M | ||
| Q1 24 | $93.1M | $191.0M |
股东权益APLSESE
| Q4 25 | $370.1M | $1.6B | ||
| Q3 25 | $401.2M | $1.5B | ||
| Q2 25 | $156.3M | $1.3B | ||
| Q1 25 | $164.2M | $1.3B | ||
| Q4 24 | $228.5M | $1.2B | ||
| Q3 24 | $237.1M | $1.2B | ||
| Q2 24 | $264.3M | $1.2B | ||
| Q1 24 | $266.7M | $1.2B |
总资产APLSESE
| Q4 25 | $1.1B | $2.4B | ||
| Q3 25 | $1.1B | $2.4B | ||
| Q2 25 | $821.4M | $2.5B | ||
| Q1 25 | $807.3M | $1.8B | ||
| Q4 24 | $885.1M | $1.8B | ||
| Q3 24 | $901.9M | $1.8B | ||
| Q2 24 | $904.5M | $1.8B | ||
| Q1 24 | $831.9M | $1.8B |
负债/权益比APLSESE
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.09× | ||
| Q3 24 | — | 0.10× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | 0.35× | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $68.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $63.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 21.7% |
| 资本支出强度资本支出/营收 | 0.1% | 2.0% |
| 现金转化率经营现金流/净利润 | — | 2.40× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $239.6M |
8季度趋势，按日历期对齐
经营现金流APLSESE
| Q4 25 | $-14.2M | $68.9M | ||
| Q3 25 | $108.5M | $109.9M | ||
| Q2 25 | $4.4M | $73.7M | ||
| Q1 25 | $-53.4M | $24.1M | ||
| Q4 24 | $19.4M | $34.2M | ||
| Q3 24 | $34.1M | $72.1M | ||
| Q2 24 | $-8.3M | $36.2M | ||
| Q1 24 | $-133.0M | $10.5M |
自由现金流APLSESE
| Q4 25 | $-14.3M | $63.0M | ||
| Q3 25 | $108.3M | $97.8M | ||
| Q2 25 | $4.4M | $64.9M | ||
| Q1 25 | $-53.4M | $14.0M | ||
| Q4 24 | $19.3M | $29.0M | ||
| Q3 24 | — | $60.9M | ||
| Q2 24 | $-8.4M | $27.6M | ||
| Q1 24 | $-133.3M | $2.0M |
自由现金流率APLSESE
| Q4 25 | -7.1% | 21.7% | ||
| Q3 25 | 23.6% | 34.1% | ||
| Q2 25 | 2.5% | 21.9% | ||
| Q1 25 | -32.0% | 5.3% | ||
| Q4 24 | 9.1% | 11.7% | ||
| Q3 24 | — | 20.4% | ||
| Q2 24 | -4.2% | 10.6% | ||
| Q1 24 | -77.3% | 0.8% |
资本支出强度APLSESE
| Q4 25 | 0.1% | 2.0% | ||
| Q3 25 | 0.0% | 4.2% | ||
| Q2 25 | 0.0% | 3.0% | ||
| Q1 25 | 0.0% | 3.8% | ||
| Q4 24 | 0.0% | 2.1% | ||
| Q3 24 | 0.0% | 3.8% | ||
| Q2 24 | 0.0% | 3.3% | ||
| Q1 24 | 0.2% | 3.4% |
现金转化率APLSESE
| Q4 25 | — | 2.40× | ||
| Q3 25 | 0.50× | 0.50× | ||
| Q2 25 | — | 2.83× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | 2.10× | ||
| Q2 24 | — | 1.24× | ||
| Q1 24 | — | 0.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ESE
| US Government | $98.0M | 34% |
| Utility Solutions Group | $87.5M | 30% |
| RF Shielding And Test | $58.3M | 20% |
| Commercial | $45.8M | 16% |
| Related Party | $1.3M | 0% |
